United-Guardian Q2 2026 earnings: Cosmetic sales drive 10% revenue growth

United-Guardian (NASDAQ: UG) reported Q2 2026 net sales of $3.11 million, up 10% from $2.84 million a year earlier, while diluted EPS increased to $0.16 from $0.14. Net income rose 16% to $728,579, supported by a 44% increase in cosmetic ingredient sales and higher non-operating income. Cost of sales grew faster than revenue, however, narrowing the gross margin.

Core Earnings Data

For the three months ended June 30, 2026, cosmetic ingredient demand drove United-Guardian’s sales growth. Gross profit increased more slowly than revenue because cost of sales rose approximately 17%, while lower operating expenses helped limit the effect on operating profit.

The increase in net income also reflected higher other income, including securities gains, settlement income and an asset-sale gain.

Gross profit and margin figures are calculated from the reported net sales and cost of sales. The results were unaudited.

Business and Segment Performance

Cosmetic ingredient sales increased 44% from the prior-year quarter. Management attributed the improvement primarily to higher purchases by Ashland Specialty Ingredients, United-Guardian’s largest cosmetic distributor. ASI had carried higher-than-normal inventory during 2025, but reduced those holdings and resumed regular purchasing levels during the first half of 2026.

Pharmaceutical sales grew 1% in the quarter, with Renacidin, the company’s most important pharmaceutical product, identified as the primary growth driver. The limited quarterly increase contrasted with 11% pharmaceutical growth for the first six months of 2026. Cosmetic ingredient sales increased 34% over the same six-month period.

For the first half of 2026, net sales rose 12% to $5.98 million and net income increased 30% to $1.55 million. These figures cover the six months ended June 30 and are separate from the quarterly results above.

Cost of Sales Outpaced Revenue, While Other Income Lifted Net Profit

Cost of sales increased to $1.56 million from $1.34 million, outpacing the 10% rise in net sales and reducing the calculated gross margin to approximately 49.7% from 52.8%. The release did not specify why the cost ratio increased.

Below the gross profit line, operating expenses declined to $667,282 from $694,050, partially offset by research and development spending rising to $124,395 from $107,868. Combined operating expenses and R&D decreased slightly, helping operating income grow despite the gross-margin contraction.

The quarter’s earnings growth was not solely operational. Other income increased by $68,331 and accounted for approximately 54% of the increase in pretax income. That improvement included a higher gain on marketable securities, $36,360 of settlement income and an $8,310 asset-sale gain, neither of which appeared in the prior-year quarter.

Management Priorities

Management’s 2026 growth plan centers on expanding promotion and market awareness for Renacidin, particularly among physicians and care providers. The company also plans to increase awareness of its natural products and expand its medical lubricant business. No quantitative financial guidance accompanied these priorities.

Risks Investors Need to Watch

• Dependence on distributor purchasing patterns: The 44% cosmetic ingredient increase was primarily tied to ASI returning to regular purchasing after reducing elevated inventory. Changes in that distributor’s inventory or ordering cadence could affect future sales comparisons.
• Gross-margin pressure: Cost of sales grew faster than revenue in Q2, reducing gross margin by approximately three percentage points. Continued cost growth at this rate would limit operating leverage.
• Concentration of pharmaceutical growth: Renacidin remained the main driver of pharmaceutical sales, while total pharmaceutical growth was only 1% for the quarter. Progress in promoting the product will be important to broader growth in this category.
• Contribution from other income: Securities gains, settlement income and an asset-sale gain materially supported pretax growth. These items may not contribute at the same level in future quarters.

Summary

United-Guardian’s Q2 2026 results reflected a rebound in cosmetic ingredient orders and continued, though modest, pharmaceutical growth. Lower operating expenses and higher other income supported earnings, but the decline in gross margin showed that revenue growth did not translate fully into operating leverage. The main issues to monitor are the durability of ASI’s normalized purchasing, the cost-of-sales ratio and whether Renacidin promotion can accelerate pharmaceutical growth.